Larimar Therapeutics Inc (LRMR)
9.39
-0.30
(-3.10%)
USD |
NASDAQ |
Jun 14, 16:00
9.38
-0.01
(-0.11%)
After-Hours: 20:00
Larimar Therapeutics Research and Development Expense (Quarterly): 12.94M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.94M |
| December 31, 2023 | 10.65M |
| September 30, 2023 | 6.585M |
| June 30, 2023 | 5.875M |
| March 31, 2023 | 4.562M |
| December 31, 2022 | 7.218M |
| September 30, 2022 | 5.582M |
| June 30, 2022 | 5.644M |
| March 31, 2022 | 5.806M |
| December 31, 2021 | 6.292M |
| Date | Value |
|---|---|
| September 30, 2021 | 14.03M |
| June 30, 2021 | 9.102M |
| March 31, 2021 | 8.974M |
| December 31, 2020 | 10.57M |
| September 30, 2020 | 6.919M |
| June 30, 2020 | 8.907M |
| March 31, 2020 | 5.007M |
| December 31, 2019 | 5.406M |
| September 30, 2019 | 8.034M |
| June 30, 2019 | 3.128M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.128M
Minimum
Jun 2019
14.03M
Maximum
Sep 2021
7.562M
Average
6.752M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen Inc | 452.90M |
| Eli Lilly and Co | 2.523B |
| PTC Therapeutics Inc | 116.13M |
| Design Therapeutics Inc | 9.801M |
| CEL-SCI Corp | 4.628M |